[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWU0JqbWdTc9cH4OY6uOsA0ifJPeYN2yRBTLrvcRKs2k":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":39,"rows":46},"Zimmer Biomet",[4],275,false,73,3,49406,0,268,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Osteoarthritis",61,{"name":18,"count":19},"Rheumatoid Arthritis",55,{"name":21,"count":22},"Avascular Necrosis",39,{"name":24,"count":25},"Traumatic Arthritis",24,{"name":27,"count":28},"Osteoarthritis, Knee",15,{"name":30,"count":31},"Osteoarthritis, Hip",14,{"name":33,"count":34},"Inflammatory Arthritis",10,{"name":36,"count":37},"Avascular Necrosis of Hip",9,[],[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,75,113,146,171,189],{"intervention":48,"totalTrials":49,"cells":50},"PRP Injection with eccentric exercises",1,{"EARLY_PHASE1":51,"PHASE1":53,"PHASE2":55,"PHASE3":57,"PHASE4":59,"NA":73},{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[],{"trials":58,"activeCount":11},[],{"trials":60,"activeCount":11},[61],{"nctId":62,"briefTitle":63,"status":64,"phases":65,"primaryCompletion":66,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":72},"NCT00761423","The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial","COMPLETED",[44],"2009-02","2009-08","2008-08",81,[71],"Achilles Tendinopathy",[48],{"trials":74,"activeCount":11},[],{"intervention":76,"totalTrials":77,"cells":78},"Corticosteroid",2,{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":99},{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[],{"trials":84,"activeCount":11},[],{"trials":86,"activeCount":11},[],{"trials":88,"activeCount":11},[89],{"nctId":90,"briefTitle":91,"status":64,"phases":92,"primaryCompletion":93,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":98},"NCT00758641","Platelet Rich Plasma to Treat Plantar Fasciitis",[44],"2016-01","2009-09",115,[97],"Plantar Fasciitis",[76],{"trials":100,"activeCount":11},[101],{"nctId":102,"briefTitle":103,"status":64,"phases":104,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":111},"NCT00757289","Platelet-rich-plasma Treating Tennis Elbow",[45],"2008-01","2009-01","2007-08",106,[110],"Pain",[112,76],"PRP",{"intervention":114,"totalTrials":77,"cells":115},"APS",{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":135},{"trials":117,"activeCount":11},[],{"trials":119,"activeCount":11},[120],{"nctId":121,"briefTitle":122,"status":64,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":128},"NCT02262364","Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)",[41],"2016-10","2014-11",11,[27],[114],{"trials":130,"activeCount":11},[],{"trials":132,"activeCount":11},[],{"trials":134,"activeCount":11},[],{"trials":136,"activeCount":11},[137],{"nctId":138,"briefTitle":139,"status":64,"phases":140,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":145},"NCT02580643","Prospective Post-Market Data Collection on Patients With Knee OA and Treated With nSTRIDE APS",[],"2019-06-30","2016-05",78,[27],[114],{"intervention":147,"totalTrials":49,"cells":148},"Leukocyte- and Platelet-Rich Plasma",{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":159},{"trials":150,"activeCount":11},[],{"trials":152,"activeCount":11},[],{"trials":154,"activeCount":11},[],{"trials":156,"activeCount":11},[],{"trials":158,"activeCount":11},[],{"trials":160,"activeCount":11},[161],{"nctId":162,"briefTitle":163,"status":164,"phases":165,"primaryCompletion":166,"completion":166,"start":142,"enrollment":167,"conditions":168,"interventions":170},"NCT02588040","Recover L-PRP in Lateral Epicondylitis (REGP-11-00)","TERMINATED",[],"2017-09",18,[169],"Lateral Epicondylitis",[147],{"intervention":112,"totalTrials":49,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":183},{"trials":174,"activeCount":11},[],{"trials":176,"activeCount":11},[],{"trials":178,"activeCount":11},[],{"trials":180,"activeCount":11},[],{"trials":182,"activeCount":11},[],{"trials":184,"activeCount":11},[185],{"nctId":102,"briefTitle":103,"status":64,"phases":186,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":187,"interventions":188},[45],[110],[112,76],{"intervention":190,"totalTrials":49,"cells":191},"Cellentra VCBM",{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":193,"activeCount":11},[],{"trials":195,"activeCount":11},[],{"trials":197,"activeCount":11},[],{"trials":199,"activeCount":11},[],{"trials":201,"activeCount":11},[],{"trials":203,"activeCount":11},[204],{"nctId":205,"briefTitle":206,"status":64,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":69,"conditions":210,"interventions":212},"NCT02182843","Cellentra Viable Cell Bone Matrix (VCBM) Anterior Cervical Discectomy and Fusion Outcomes Study (VCBM\u002FMaxAn)",[45],"2018-01","2014-03",[211],"Cervical Disc Degenerative Disorder",[190]]